Van ECK Associates Corp cut its holdings in Centene Co. (NYSE:CNC – Free Report) by 18.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,199 shares of the company’s stock after selling 1,396 shares during the period. Van ECK Associates Corp’s holdings in Centene were worth $392,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Coppell Advisory Solutions Corp. purchased a new stake in Centene in the 4th quarter valued at about $25,000. Arlington Partners LLC purchased a new position in Centene in the first quarter valued at approximately $35,000. Compagnie Lombard Odier SCmA acquired a new position in Centene during the fourth quarter valued at approximately $41,000. Centerpoint Advisors LLC purchased a new stake in Centene during the first quarter worth approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of Centene by 91.4% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 666 shares of the company’s stock valued at $42,000 after acquiring an additional 318 shares during the period. Institutional investors and hedge funds own 90.11% of the company’s stock.
Centene Stock Up 1.6 %
CNC stock opened at $66.83 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The firm’s 50-day simple moving average is $66.87 and its 200 day simple moving average is $67.87. The stock has a market cap of $36.19 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 0.91 and a beta of 0.57. Centene Co. has a fifty-two week low of $61.34 and a fifty-two week high of $98.53.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Mizuho cut their price objective on Centene from $80.00 to $76.00 in a research report on Tuesday, July 11th. Morgan Stanley reaffirmed an “overweight” rating and set a $94.00 target price on shares of Centene in a research report on Friday, July 14th. Wolfe Research downgraded Centene from an “outperform” rating to a “peer perform” rating in a report on Wednesday, July 12th. Stephens reduced their target price on Centene from $87.00 to $85.00 in a research note on Monday, July 31st. Finally, UBS Group started coverage on shares of Centene in a report on Tuesday, June 20th. They issued a “neutral” rating and a $72.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $86.11.
Read Our Latest Analysis on CNC
Centene Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. It operates in two segments, Managed Care and Specialty Services. The Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs.
Recommended Stories
- Five stocks we like better than Centene
- Profitably Trade Stocks at 52-Week Highs
- 8 Best Meme Stocks to Buy Now
- P/E Ratio Calculation: How to Assess Stocks
- Is Now The Time To Buy XLF Financial ETF?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Three Ways To Play The Rise In Oil Prices
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.